| Patient Numbers |
Dutasteride
(N = 3,305) |
Placebo
(N = 3,424) |
Relative Risk |
| Resource |
n |
Percentage (95% CI) |
n |
Percentage (95% CI) |
Estimate |
95% CI |
| Concomitant Medications |
841 |
25 (24, 27) |
994 |
29 (28, 31) |
1.14 |
1.05, 1.23 |
| Alpha-blockers |
713 |
22 (20, 23) |
862 |
25 (24, 27) |
1.17 |
1.07, 1.27 |
| Health Care Visits |
|
|
|
|
|
|
| Surgical procedures |
60 |
2 (1, 2) |
188 |
5 (5, 6) |
3.02 |
2.27, 4.03 |
| Nonsurgical procedures |
5 |
0 (0, 0) |
12 |
0 (0, 1) |
2.32 |
0.82, 6.57 |
| Unscheduled biopsies |
322 |
10 (9, 11) |
470 |
14 (13, 15) |
1.41 |
1.23, 1.61 |
| UTI |
186 |
6 (5, 6) |
299 |
9 (8, 10) |
1.55 |
1.30, 1.85 |
| AUR |
53 |
2 (1, 2) |
230 |
7 (6, 8) |
4.19 |
3.12, 5.62 |
| Macroscopic hematuria |
114 |
3 (3, 4) |
171 |
5 (4, 6) |
1.45 |
1.15, 1.83 |
| Macroscopic hematospermia |
43 |
1 (1, 2) |
35 |
1 (1, 1) |
0.79 |
0.50, 1.22 |
AUR = acute urinary retention; CI = confidence interval; UTI = urinary tract infection.
aTable presents the proportions of patients within each treatment group who experience at least one episode of each resource. |